Form 8-K · Current Report · Filed 2025-11-17
BD Announces Additions to Board of Directors
On November 17, 2025, Becton, Dickinson and Company (BD) announced the election of Robert L.
- Filer
- Becton, Dickinson and Company BDX · NYSE
- Filed
- Accession
- 0001628280-25-052625
- CIK
- 0000010795
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Details
Huffines and Jacqueline Wright to its Board of Directors, effective December 1, 2025. The addition of these independent directors will expand the Board from twelve to fourteen members, with Huffines joining the Audit and Corporate Governance and Nominating Committees, and Wright joining the Audit and Compensation and Human Capital Committees.
Items reported
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Financial Statements and Exhibits
Market reaction
Close before filing
$151.76
Next session
-0.4%
Since filing
+9.1%
Latest close
$165.62
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from BDX reporting the same item, with the next session's move:
About Becton, Dickinson and Company
Becton, Dickinson and Company, commonly known as BD, is a prominent American multinational corporation engaged in the development and manufacture of a diverse range of medical devices, instrument systems, and reagents. A key player in the healthcare industry, BD focuses on improving medical discovery, diagnostics, and the delivery of care. BD's products are instrumental in supporting healthcare professionals worldwide in enhancing patient safety and reducing the risks associated with healthcare workers. The company operates across three main segments: BD Medical, BD Life Sciences, and BD Interventional, impacting various sectors such as pharmaceuticals, hospital healthcare systems, and clinical laboratories. With a strong commitment to innovation and quality, Becton, Dickinson and Company contributes significantly to advancements in patient care, operating efficiency in medical settings, and is noted for its commitment to addressing healthcare challenges on a global scale. Headquartered in Franklin Lakes, New Jersey, BD maintains a robust presence across numerous countries, underpinning its influential role in the evolution and improvement of global healthcare infrastructure.
Never miss another BDX filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.